JP2003513045A - 便秘及び過敏性大腸症候群を治療・処置するための組成物 - Google Patents
便秘及び過敏性大腸症候群を治療・処置するための組成物Info
- Publication number
- JP2003513045A JP2003513045A JP2001534385A JP2001534385A JP2003513045A JP 2003513045 A JP2003513045 A JP 2003513045A JP 2001534385 A JP2001534385 A JP 2001534385A JP 2001534385 A JP2001534385 A JP 2001534385A JP 2003513045 A JP2003513045 A JP 2003513045A
- Authority
- JP
- Japan
- Prior art keywords
- release
- opioid antagonist
- antagonist
- opioid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 206010010774 Constipation Diseases 0.000 title claims abstract description 29
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims abstract description 19
- 229960004127 naloxone Drugs 0.000 claims abstract description 34
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims abstract description 34
- 239000003401 opiate antagonist Substances 0.000 claims abstract description 31
- 238000013268 sustained release Methods 0.000 claims abstract description 23
- 239000012730 sustained-release form Substances 0.000 claims abstract description 22
- 210000000813 small intestine Anatomy 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 210000001815 ascending colon Anatomy 0.000 claims abstract description 16
- 210000001072 colon Anatomy 0.000 claims abstract description 8
- 230000003111 delayed effect Effects 0.000 claims abstract description 8
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims abstract description 8
- 229960003086 naltrexone Drugs 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims description 24
- 239000011159 matrix material Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000002702 enteric coating Substances 0.000 claims description 10
- 238000009505 enteric coating Methods 0.000 claims description 10
- 125000005456 glyceride group Chemical group 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 210000003405 ileum Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 abstract description 8
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 16
- 230000000968 intestinal effect Effects 0.000 description 13
- 229920003134 Eudragit® polymer Polymers 0.000 description 10
- 229940005483 opioid analgesics Drugs 0.000 description 9
- 229960004126 codeine Drugs 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 208000030053 Opioid-Induced Constipation Diseases 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000013872 defecation Effects 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- -1 methyl natrexone Chemical class 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 description 2
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004415 codeine phosphate Drugs 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229960002921 methylnaltrexone Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000000014 opioid analgesic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 208000012488 Opiate Overdose Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PQKHESYTSKMWFP-WZJCLRDWSA-N beta-Funaltrexamine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3NC(=O)/C=C/C(=O)OC)CN2CC1CC1 PQKHESYTSKMWFP-WZJCLRDWSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940082337 dimethicone 20 Drugs 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960003577 mebeverine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FOXFZRUHNHCZPX-UHFFFAOYSA-N metribuzin Chemical compound CSC1=NN=C(C(C)(C)C)C(=O)N1N FOXFZRUHNHCZPX-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- AJPSBXJNFJCCBI-YOHUGVJRSA-N naloxonazine Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 AJPSBXJNFJCCBI-YOHUGVJRSA-N 0.000 description 1
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9925872.5 | 1999-11-01 | ||
| GB9925872A GB9925872D0 (en) | 1999-11-01 | 1999-11-01 | Composition for relief of constipation |
| GB9928314.5 | 1999-11-30 | ||
| GB9928314A GB9928314D0 (en) | 1999-11-30 | 1999-11-30 | Composition for the treatment of irritable bowel syndrome |
| PCT/GB2000/004167 WO2001032180A2 (en) | 1999-11-01 | 2000-10-30 | Composition for treatment of constipation and irritable bowel syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003513045A true JP2003513045A (ja) | 2003-04-08 |
| JP2003513045A5 JP2003513045A5 (enExample) | 2007-11-01 |
Family
ID=26316047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001534385A Pending JP2003513045A (ja) | 1999-11-01 | 2000-10-30 | 便秘及び過敏性大腸症候群を治療・処置するための組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6734188B1 (enExample) |
| EP (1) | EP1225897B1 (enExample) |
| JP (1) | JP2003513045A (enExample) |
| AT (1) | ATE275402T1 (enExample) |
| AU (1) | AU776567B2 (enExample) |
| CA (1) | CA2389650C (enExample) |
| CZ (1) | CZ299726B6 (enExample) |
| DE (1) | DE60013630T2 (enExample) |
| DK (1) | DK1225897T3 (enExample) |
| ES (1) | ES2226933T3 (enExample) |
| IL (2) | IL149378A0 (enExample) |
| PT (1) | PT1225897E (enExample) |
| WO (1) | WO2001032180A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014129397A (ja) * | 2002-04-05 | 2014-07-10 | Euro-Celtique Sa | オキシコドン及びナロキソンを含有する医薬製剤 |
| JP2015531770A (ja) * | 2012-08-29 | 2015-11-05 | サリックス ファーマシューティカルズ，インコーポレイテッド | 緩下剤組成物、ならびに便秘および関連胃腸疾患および症状を処置するための方法 |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1685839T3 (da) | 1997-12-22 | 2013-06-24 | Euro Celtique Sa | Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist |
| PT1225897E (pt) | 1999-11-01 | 2005-01-31 | John Rhodes | Composicao para o tratamento da obstipacao e do sindroma do intestino irritavel |
| AU776666B2 (en) | 2000-02-08 | 2004-09-16 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| CN1525851A (zh) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
| US7943173B2 (en) | 2001-07-18 | 2011-05-17 | Purdue Pharma L.P. | Pharmaceutical combinations of oxycodone and naloxone |
| US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
| WO2003013525A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
| US7501433B2 (en) * | 2002-05-17 | 2009-03-10 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| DK1551372T3 (en) | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
| ATE477268T1 (de) | 2003-01-28 | 2010-08-15 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur behandlung von magen-darm- störungen |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| HRP20150037T4 (hr) | 2003-04-08 | 2022-09-02 | Progenics Pharmaceuticals, Inc. | Farmaceutske formulacije koje sadrže metilnaltrekson |
| JP2006522817A (ja) * | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用 |
| TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
| US8017622B2 (en) * | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| ES2314646T3 (es) * | 2004-03-22 | 2009-03-16 | Solvay Pharmaceuticals Gmbh | Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos. |
| TW200633721A (en) * | 2004-12-14 | 2006-10-01 | Shionogi & Co | A pharmaceutical composition for treating constipation |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| CN101171010B (zh) | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| HUE031042T2 (en) * | 2005-07-29 | 2017-06-28 | Abbott Laboratories Gmbh | Methods for producing pancreatin powder with low viral content |
| US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| US9198871B2 (en) * | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| EP1931316B2 (en) * | 2005-08-15 | 2017-02-22 | Abbott Laboratories GmbH | Controlled release pharmaceutical compositions for acid labile drugs |
| US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
| AU2007240873A1 (en) * | 2006-04-19 | 2007-11-01 | Jill P. Smith | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
| US10072256B2 (en) * | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| KR101486228B1 (ko) | 2006-06-19 | 2015-01-26 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| US20100048519A1 (en) * | 2006-09-13 | 2010-02-25 | Chyon-Hwa Yeh | Methods of treatment for ulcerative colitis using aminosalicylate |
| AU2006348180A1 (en) * | 2006-09-13 | 2008-03-20 | Warner Chilcott Company, Llc | Methods of treatment for ulcerative colitis |
| US8546418B2 (en) | 2007-03-29 | 2013-10-01 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
| PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
| CA2682129A1 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms and uses thereof |
| MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
| US8883817B2 (en) * | 2007-10-18 | 2014-11-11 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
| US20090130063A1 (en) * | 2007-11-15 | 2009-05-21 | Solvay Pharmaceuticals Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| EP2240489A1 (en) | 2008-02-06 | 2010-10-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| KR20110004425A (ko) * | 2008-05-07 | 2011-01-13 | 넥타르 테라퓨틱스 | 말초적 작용 오피오이드 길항제의 경구 투여 |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| KR20170091783A (ko) | 2008-12-31 | 2017-08-09 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법 |
| WO2010103039A1 (en) | 2009-03-10 | 2010-09-16 | Euro-Celtique S.A. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| US20120040009A1 (en) * | 2009-04-22 | 2012-02-16 | Lars Holger Hermann | Particulate pharmaceutical composition with an opioid and an opioid antagonist |
| JP5797655B2 (ja) * | 2009-09-18 | 2015-10-21 | アドラー・コーポレーション | 消化管障害のためのオピオイド受容体アンタゴニストの使用 |
| NZ603173A (en) | 2010-05-10 | 2014-10-31 | Euro Celtique Sa | Manufacturing of active-free granules and tablets comprising the same |
| WO2011141490A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
| AU2013304812B2 (en) | 2012-08-21 | 2016-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| SMT201900386T1 (it) | 2013-04-12 | 2019-09-09 | Ardelyx Inc | Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato |
| KR20180037074A (ko) | 2013-07-23 | 2018-04-10 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
| EP3068397A1 (en) | 2013-11-13 | 2016-09-21 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
| EP3229785A2 (de) * | 2014-12-08 | 2017-10-18 | Develco Pharma Schweiz AG | Naloxon-monopräparat und mehrschichttablette |
| US20160256451A1 (en) * | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Dosage of naloxone |
| WO2016193456A2 (en) * | 2015-06-03 | 2016-12-08 | Develco Pharma Schweiz Ag | Opioid receptor antagonist for use in treating patients with severe constipation |
| US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
| US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
| AU2018205400C1 (en) | 2017-01-09 | 2026-01-15 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
| JP2020505333A (ja) | 2017-01-09 | 2020-02-20 | アルデリックス， インコーポレイテッド | Ｎｈｅ媒介性アンチポートの阻害薬 |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| WO2023102491A1 (en) * | 2021-12-01 | 2023-06-08 | Invea Therapeutics, Inc. | Methods for treating gastrointestinal inflammatory disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997028801A1 (en) * | 1996-02-09 | 1997-08-14 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| WO1998002188A1 (en) * | 1996-07-16 | 1998-01-22 | Mayo Foundation For Medical Education And Research | Intestinal absorption of nicotine to treat nicotine responsive conditions |
| WO1999016436A1 (en) * | 1997-09-30 | 1999-04-08 | John Rhodes | Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
| DE3381877D1 (de) | 1982-03-16 | 1990-10-18 | Univ Rockefeller | Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen. |
| IT1188550B (it) * | 1986-02-07 | 1988-01-14 | Sclavo Spa | Peptide sintetico ad attivita' interleukina 1 umana |
| US4774230A (en) | 1988-03-26 | 1988-09-27 | Ivax Laboratories, Inc. | Glucuronic acid derivatives of opioid antagonists |
| HU218673B (hu) | 1993-10-07 | 2000-10-28 | Euroceltique S.A. | Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására |
| US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| IT1298575B1 (it) * | 1998-02-06 | 2000-01-12 | Vectorpharma Int | Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di |
| WO2000003660A1 (en) | 1998-07-17 | 2000-01-27 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
| PT1225897E (pt) | 1999-11-01 | 2005-01-31 | John Rhodes | Composicao para o tratamento da obstipacao e do sindroma do intestino irritavel |
-
2000
- 2000-10-30 PT PT00971617T patent/PT1225897E/pt unknown
- 2000-10-30 US US10/111,850 patent/US6734188B1/en not_active Expired - Fee Related
- 2000-10-30 AT AT00971617T patent/ATE275402T1/de active
- 2000-10-30 JP JP2001534385A patent/JP2003513045A/ja active Pending
- 2000-10-30 ES ES00971617T patent/ES2226933T3/es not_active Expired - Lifetime
- 2000-10-30 IL IL14937800A patent/IL149378A0/xx active IP Right Grant
- 2000-10-30 DE DE60013630T patent/DE60013630T2/de not_active Expired - Lifetime
- 2000-10-30 AU AU10447/01A patent/AU776567B2/en not_active Ceased
- 2000-10-30 CA CA002389650A patent/CA2389650C/en not_active Expired - Fee Related
- 2000-10-30 WO PCT/GB2000/004167 patent/WO2001032180A2/en not_active Ceased
- 2000-10-30 CZ CZ20021536A patent/CZ299726B6/cs not_active IP Right Cessation
- 2000-10-30 DK DK00971617T patent/DK1225897T3/da active
- 2000-10-30 EP EP00971617A patent/EP1225897B1/en not_active Expired - Lifetime
-
2002
- 2002-04-28 IL IL149378A patent/IL149378A/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997028801A1 (en) * | 1996-02-09 | 1997-08-14 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| WO1998002188A1 (en) * | 1996-07-16 | 1998-01-22 | Mayo Foundation For Medical Education And Research | Intestinal absorption of nicotine to treat nicotine responsive conditions |
| WO1999016436A1 (en) * | 1997-09-30 | 1999-04-08 | John Rhodes | Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014129397A (ja) * | 2002-04-05 | 2014-07-10 | Euro-Celtique Sa | オキシコドン及びナロキソンを含有する医薬製剤 |
| JP2015531770A (ja) * | 2012-08-29 | 2015-11-05 | サリックス ファーマシューティカルズ，インコーポレイテッド | 緩下剤組成物、ならびに便秘および関連胃腸疾患および症状を処置するための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK1225897T3 (da) | 2005-01-10 |
| WO2001032180A3 (en) | 2001-09-20 |
| US6734188B1 (en) | 2004-05-11 |
| PT1225897E (pt) | 2005-01-31 |
| HK1048595A1 (en) | 2003-04-11 |
| DE60013630D1 (de) | 2004-10-14 |
| IL149378A0 (en) | 2002-11-10 |
| EP1225897B1 (en) | 2004-09-08 |
| IL149378A (en) | 2006-12-31 |
| CZ299726B6 (cs) | 2008-11-05 |
| ATE275402T1 (de) | 2004-09-15 |
| AU776567B2 (en) | 2004-09-16 |
| WO2001032180A2 (en) | 2001-05-10 |
| AU1044701A (en) | 2001-05-14 |
| DE60013630T2 (de) | 2005-09-15 |
| ES2226933T3 (es) | 2005-04-01 |
| CA2389650A1 (en) | 2001-05-10 |
| EP1225897A2 (en) | 2002-07-31 |
| CZ20021536A3 (cs) | 2003-02-12 |
| CA2389650C (en) | 2008-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU776567B2 (en) | Composition for treatment of constipation and irritable bowel syndrome | |
| US10588865B2 (en) | Tamper resistant oral opioid agonist formulations | |
| JP5566102B2 (ja) | 医薬組成物 | |
| JP2010506833A (ja) | 医薬組成物 | |
| HK1048595B (en) | Composition for treatment of constipation and irritable bowel syndrome | |
| HK1056822B (en) | Tamper-resistant oral opioid agonist formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040628 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070910 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070910 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100820 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101210 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110219 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110706 |